ArticleMikrochimica acta2026
One nanozyme, three functions: substrate-switchable Cu-NH₂-BDC nanozyme for multiplexed biosensing in physiological environments.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
An amino-functionalized copper-based metal–organic framework (Cu–NH₂–BDC) is reported that integrates intrinsic fluorescence with versatile catalytic functions, including oxidase (OXD), peroxidase (POD), and laccase (LAC) activities. Engineering amino group and the central metal node enables Cu–NH₂–BDC to overcome the intrinsic pH limitations of most nanozymes, achieving its highest catalytic efficiency at physiological pH (7.4). Remarkably, Cu–NH₂–BDC exhibits substrate-switchable catalytic behavior, in which the substrate itself directs the dominant enzymatic pathway. This unique mechanism allows precise regulation of substrate-specific catalytic signaling while minimizing interference among multiple catalytic modes. Leveraging these properties, we established a triple-mode biosensing platform capable of highly sensitive and selective detection of acetylcholinesterase (AChE; LOD = 0.001 mU/mL), dopamine (DA; LOD = 0.048 µg/mL), and ascorbic acid (AA; LOD = 0.6 µM) under physiological conditions. This work introduces a novel substrate-engineering strategy for modulating multi-colorimetric signal in nanozymes and provides a powerful and generalizable approach for developing intelligent multifunctional biosensors.
Indexed as
Identifiers
41764107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.